Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
Clinical trial NCT07122063 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07122063
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-11
- Primary completion
- 2027-07-30
- Enrollment
- 266
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.